Edition:
United States

Array Biopharma Inc (ARRY.OQ)

ARRY.OQ on NASDAQ Stock Exchange Global Market

11.12USD
3:59pm EST
Change (% chg)

$-0.37 (-3.22%)
Prev Close
$11.49
Open
$11.49
Day's High
$11.60
Day's Low
$11.12
Volume
939,925
Avg. Vol
939,537
52-wk High
$13.38
52-wk Low
$6.74

Latest Key Developments (Source: Significant Developments)

Array - In Exchange For $126.06 Million 3.00% Convertible Senior Notes Co Issued 2024 $126.06 Million Notes
Monday, 4 Dec 2017 04:42pm EST 

Dec 4 (Reuters) - Array Biopharma Inc ::ARRAY BIOPHARMA - ‍ON DEC 1, IN EXCHANGE FOR $126.06 MILLION OF 3.00% CONVERTIBLE SENIOR NOTES DUE 2020 CO ISSUED 2024 NOTES OF $126.06 MILLION.ARRAY BIOPHARMA SAYS ‍2024 NOTES WILL MATURE ON DEC 1, 2024​ - SEC FILING.ARRAY - ALSO ISSUED AGGREGATE OF ABOUT 7.96 MILLION SHARES OF CO'S COMMON STOCK IN EXCHANGE OF $126.06 MILLION OF 3.00% CONVERTIBLE SENIOR NOTES DUE 2020​.ARRAY BIOPHARMA - ‍2024 NOTES TO BEAR INTEREST AT 2.625% PAYABLE SEMIANNUALLY IN ARREARS ON JUNE 1 & DEC 1 OF EACH YEAR, BEGINNING JUNE 1, 2018​.  Full Article

Array Biopharma reports initial results from novel immunotherapy combination at SITC annual meeting
Monday, 13 Nov 2017 08:00am EST 

Nov 13 (Reuters) - Array Biopharma Inc :Array biopharma reports initial results from novel immunotherapy combination at the Society For Immunotherapy Of Cancer (SITC) 32nd annual meeting.Array Biopharma Inc - ‍plans to expand ongoing phase 2 CSF1R + PD1 combination study into other tumor types including pancreatic cancer​.  Full Article

ARRAY BIOPHARMA REPORTS Q1 LOSS PER SHARE $0.22
Tuesday, 31 Oct 2017 08:00am EDT 

Oct 31 (Reuters) - Array Biopharma Inc :ARRAY BIOPHARMA REPORTS FINANCIAL RESULTS FOR THE FIRST QUARTER OF FISCAL 2018.Q1 LOSS PER SHARE $0.22.Q1 REVENUE $29.7 MILLION VERSUS I/B/E/S VIEW $33.3 MILLION.Q1 EARNINGS PER SHARE VIEW $-0.22 -- THOMSON REUTERS I/B/E/S.‍INCREASE IN QTRLY NET LOSS WAS PRIMARILY DUE TO A DECREASE IN REIMBURSEMENT REVENUE FROM NOVARTIS​.‍INCREASE IN QTRLY NET LOSS WAS ALSO PRIMARILY DUE TO A DECREASE IN NON-RECURRING COSTS FOR COMMERCIAL DRUG SUPPLY FROM NOVARTIS​.  Full Article

Array Biopharma announces proposed public offering of common stock
Wednesday, 13 Sep 2017 04:02pm EDT 

Sept 14 (Reuters) - Array Biopharma Inc :Array Biopharma announces proposed public offering of common stock.Array Biopharma Inc - ‍commenced an underwritten public offering of $175 million of shares of its common stock.​.  Full Article

Point72 Asset Management reports 5.4 percent passive stake in Array Biopharma Inc
Tuesday, 12 Sep 2017 05:34pm EDT 

Sept 12 (Reuters) - Array Biopharma Inc :Point72 Asset Management L.P reports 5.4 percent passive stake in Array Biopharma Inc as of September 11, 2017 - SEC filing‍​.  Full Article

Array Biopharma announces FDA acceptance for review of Binimetinib and Encorafenib new drug applications for patients with advanced BRAF-mutant melanoma
Tuesday, 12 Sep 2017 09:10am EDT 

Sept 12 (Reuters) - Array Biopharma Inc :Array Biopharma announces FDA acceptance for review of Binimetinib and Encorafenib new drug applications for patients with advanced BRAF-mutant melanoma.Array Biopharma Inc - ‍FDA informed array that based on their preliminary review of applications they have not identified any potential review issues​.Array Biopharma Inc - ‍FDA set a target action date under pdufa of june 30, 2018 for both applications​.Array Biopharma Inc - ‍fda informed array that they are not currently planning to hold an advisory committee meeting to discuss NDAs​.  Full Article

Array Biopharma reports Q4 loss per share $0.17
Wednesday, 9 Aug 2017 06:00am EDT 

Aug 9 (Reuters) - Array Biopharma Inc :Array Biopharma reports financial results for the fourth quarter and full year of fiscal 2017.Q4 loss per share $0.17.Q4 revenue $33.8 million versus I/B/E/S view $28.6 million.Q4 earnings per share view $-0.21 -- Thomson Reuters I/B/E/S.Array Biopharma Inc - ‍Entered into a license, development and commercialization partnership with Ono Pharmaceutical for binimetinib and encorafenib​.Array Biopharma Inc - ‍Ono received rights to develop and commercialize binimetinib and encorafenib in Japan and South Korea​.Array Biopharma - ‍Received upfront payment of $31.2 million, retains exclusive commercialization rights for binimetinib, encorafenib in U.S., Canada, Israel​.Array Biopharma Inc - ‍Is entitled to receive up to an additional $156 million (¥17.3 billion) if certain development and commercial milestones are achieved​.Array Biopharma Inc - ‍Will be eligible for robust, tiered, double-digit royalties based on product sales in Japan and South Korea​.  Full Article

Amgen and Array BioPharma announce preclinical license and collaboration agreement
Tuesday, 18 Jul 2017 08:00am EDT 

July 18 (Reuters) - Array BioPharma Inc :Amgen and Array BioPharma announce preclinical license and collaboration agreement in inflammation.Array BioPharma - under terms of agreement, Amgen and Array will collaborate on preclinical development with Array leading medicinal chemistry work.Array BioPharma Inc - ‍Amgen is responsible for clinical development and commercialization​.Array BioPharma - in exchange for exclusive rights to Array's preclinical program, Amgen will make upfront and milestone payments.Array BioPharma - Amgen will also pay royalties on sales of resulting therapies.  Full Article

Array Biopharma submits new drug applications to FDA
Wednesday, 5 Jul 2017 08:00am EDT 

July 5 (Reuters) - Array Biopharma Inc ::Array Biopharma submits new drug applications to FDA for binimetinib and encorafenib in advanced melanoma.Array Biopharma Inc - ‍further results from columbus part 2 will be presented at a medical meeting during second half of 2017​.Array Biopharma- ‍submission of two NDAs to FDA to support use of combination of binimetinib 45 mg twice daily, encorafenib 450 mg once daily.  Full Article

Ono Pharmaceutical concludes a license agreement with array biopharma related to MEK inhibitor and BRAF inhibitor
Wednesday, 31 May 2017 04:04am EDT 

May 31 (Reuters) - Ono Pharmaceutical Co Ltd <4528.T>:* Says it concluded a license agreement with Array Biopharma Inc. to develop and commercialize binimetinib, a MEK inhibitor and encorafenib, a BRAF inhibitor, in Japan and.* Says Binimetinib and encorafenib are currently in two global Phase III trials for the treatment of patients with BRAF-mutant melanoma (COLUMBUS study) and BRAF-mutant colorectal.* Under the terms of the agreement, ONO will pay to Array an upfront payment of 3.5 billion yen and milestones up to 17.3 billion yen and other expenses .  Full Article

BRIEF-Array - In Exchange For $126.06 Million 3.00% Convertible Senior Notes Co Issued 2024 $126.06 Million Notes

* ARRAY BIOPHARMA - ‍ON DEC 1, IN EXCHANGE FOR $126.06 MILLION OF 3.00% CONVERTIBLE SENIOR NOTES DUE 2020 CO ISSUED 2024 NOTES OF $126.06 MILLION